{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00225095",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Osiris 550"
      },
      "Organization": {
        "OrgFullName": "Mesoblast, Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy",
      "OfficialTitle": "A Phase I/II, Randomized, Controlled, Double Blind, Study of Chondrogen - Adult Universal Cell Delivered by Intra-Articular Injection Following Meniscectomy in Patients 18-60 Years"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2021",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 2005"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 2008",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "April 2008",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "September 21, 2005",
      "StudyFirstSubmitQCDate": "September 21, 2005",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 23, 2005",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "December 23, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 27, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Mesoblast International SÃ rl",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "University of Southern California",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Midwest Orthopedics at Rush - Chicago, IL",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Unlimited Research - San Antonio, TX",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Triangle Orthopaedic Associates, P.A.",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Orthopedic Center of Vero Beach - Vero Beach, FL",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "OrthoIndy",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "TRIA Orthopaedic Center",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Greater Chesapeake Orthopaedic Associates, LLC",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to determine whether Chondrogen is a safe and effective post-operative treatment of the knee following menisectomy (the surgical removal of all or part of a torn meniscus).",
      "DetailedDescription": "Chondrogen is a preparation of adult mesenchymal stem cells (MSCs) in a solution containing hyaluronic acid. Preclinical studies have shown that injection of Chondrogen aids in the repair of meniscal tissue following meniscectomy. In Chondrogen treated subjects, surgically removed meniscal tissue was regenerated, cartilage surface was protected, and joint damage was decreased in comparison to control subjects. These benefits persisted at least one year.\n\nThree groups of recent meniscectomy patients will be followed in this study, including patients that will receive placebo and patients that will be treated with one of two possible doses of Chondrogen."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Recovery Following Partial Medial Meniscectomy"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "meniscectomy",
          "Chondrogen",
          "Mesenchymal Stem Cells",
          "Osiris"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "60",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Chondrogen - dose 1",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Chondrogen - 50 million cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Mesenchymal Stem Cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Chondrogen - dose 2",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Chondrogen - 150 million cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Mesenchymal Stem Cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Vehicle Control",
            "ArmGroupType": "Other",
            "ArmGroupDescription": "Vehicle Control",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Hyaluronan"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Mesenchymal Stem Cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Chondrogen - dose 1",
                "Chondrogen - dose 2"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Hyaluronan",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Vehicle Control"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Meniscal Volume",
            "PrimaryOutcomeDescription": "Changes in meniscal volume over the course of the study as determined by MRI",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Quality of Life Questionnaire",
            "SecondaryOutcomeDescription": "Determination of Quality of Life will be measured by the KOOS instrument (Knee injury and Osteoarthritis Outcome Score).",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Visual Analog Scale (VAS)",
            "SecondaryOutcomeDescription": "Patient perception of pain will be documented using a single VAS pain scale.",
            "SecondaryOutcomeTimeFrame": "Baseline to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Lysholm Knee Scale",
            "SecondaryOutcomeDescription": "Lysholm knee score will be determined according to the questionnaire",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Safety Assessment Adverse Event",
            "SecondaryOutcomeDescription": "Number of participants with Adverse Events.",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Safety Assessment Immunological",
            "SecondaryOutcomeDescription": "Number of participants with clinically significant abnormalities in immunological measures",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Safety Assessment Laboratory",
            "SecondaryOutcomeDescription": "Number of participants with clinically significant abnormalities in laboratory assessments",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Safety Assessment Physical Exam",
            "SecondaryOutcomeDescription": "Number of participants with clinically significant abnormalities in physical examinations.",
            "SecondaryOutcomeTimeFrame": "2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Safety Assessment Magnetic Resonance Imaging (MRI)",
            "SecondaryOutcomeDescription": "Number of participants with clinically significant abnormalities in Magnetic Resonance Imaging (MRI).",
            "SecondaryOutcomeTimeFrame": "2 years"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge 18 to 60, inclusive\nIn need of medial meniscectomy\nNormal axial alignment\nStable knee- previous ligament reconstruction, if stable\nRemoval of at least 50% of the affected portion of the medial meniscus\nIntact articular cartilage in posterior meniscal weight-bearing zone\nWillingness to follow normal post-operative rehabilitation\nWillingness to participate in follow-up for two years from the time of meniscectomy surgery\nAbility to understand and willingness to sign consent form\n\nExclusion Criteria:\n\nPregnant or lactating\nACL or other support structure damage confirmed at surgery\nGrade III or IV cartilage damage (Cartilage loss greater than 50% thickness in area >15mm on weight-bearing aspect of femoral condyle or tibial plateau)\nSynvisc, steroid, or corticosteroid injections in preceding 3 months\nDiffuse synovitis at time of arthroscopy\nInflammatory arthritis\nOral steroid, methotrexate therapy\nUnable to follow post-operative exercise regimen or return for evaluations\nActive alcohol or substance abuse within 6 months of study entry\nCurrent and active tobacco product use\nPatient is positive for HIV\nPatient is positive for hepatitis (past history of Hepatitis A is allowed)\nAny medical condition, which in the opinion of the clinical investigator, would interfere with the treatment or outcome of the patient\nIndwelling pacemaker\nCerebral aneurysm clips\nEar, eye and penile implants with avian components\nElectrical indwelling device such as bone stimulator\nIndwelling magnets as tissue expander for future implants\nKnown allergy to avian, bovine or porcine protein",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Michelle Williams, Ph.D.",
            "OverallOfficialAffiliation": "Osiris Therapeutics, Inc.",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Southern California",
            "LocationCity": "Los Angeles",
            "LocationState": "California",
            "LocationZip": "90033",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Orthopedic Center of Vero Beach",
            "LocationCity": "Vero Beach",
            "LocationState": "Florida",
            "LocationZip": "32960",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Midwest Orthopaedics at Rush",
            "LocationCity": "Chicago",
            "LocationState": "Illinois",
            "LocationZip": "60612",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Ortholndy",
            "LocationCity": "Indianapolis",
            "LocationState": "Indiana",
            "LocationZip": "46237",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Greater Chesapeake Associates",
            "LocationCity": "Baltimore",
            "LocationState": "Maryland",
            "LocationZip": "21218",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "TRIA Orthopaedic Center",
            "LocationCity": "Bloomington",
            "LocationState": "Minnesota",
            "LocationZip": "55431",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Triangle Orthopaedics Associates, P.A.",
            "LocationCity": "Durham",
            "LocationState": "North Carolina",
            "LocationZip": "27704",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Unlimited Research",
            "LocationCity": "San Antonio",
            "LocationState": "Texas",
            "LocationZip": "78233",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "10102814",
            "ReferenceType": "background",
            "ReferenceCitation": "Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7."
          },
          {
            "ReferencePMID": "14673997",
            "ReferenceType": "background",
            "ReferenceCitation": "Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003 Dec;48(12):3464-74."
          },
          {
            "ReferencePMID": "24430407",
            "ReferenceType": "derived",
            "ReferenceCitation": "Vangsness CT Jr, Farr J 2nd, Boyd J, Dellaero DT, Mills CR, LeRoux-Williams M. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am. 2014 Jan 15;96(2):90-8. doi: 10.2106/JBJS.M.00058."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Osiris Therapeutics, Inc. Home Page",
            "SeeAlsoLinkURL": "http://www.osiristx.com"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000006820",
            "InterventionMeshTerm": "Hyaluronic Acid"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000276",
            "InterventionAncestorTerm": "Adjuvants, Immunologic"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000055675",
            "InterventionAncestorTerm": "Viscosupplements"
          },
          {
            "InterventionAncestorId": "D000020011",
            "InterventionAncestorTerm": "Protective Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M9030",
            "InterventionBrowseLeafName": "Hyaluronic Acid",
            "InterventionBrowseLeafAsFound": "Topical anesthesia",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M2780",
            "InterventionBrowseLeafName": "Adjuvants, Immunologic",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M27448",
            "InterventionBrowseLeafName": "Viscosupplements",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M21022",
            "InterventionBrowseLeafName": "Protective Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}